Brenmiller Energy Ltd surges 15.93% amid market decline
Brenmiller Energy Ltd experienced a significant price increase of 15.93% as it crossed above the 5-day SMA, showcasing strong momentum in a challenging market environment.
This surge comes amid broader market weakness, with the Nasdaq-100 down 0.50% and the S&P 500 down 0.37%. The stock's resilience suggests sector rotation as investors shift focus to renewable energy companies, which are gaining traction despite the overall market decline.
The implications of this movement indicate a potential shift in investor sentiment towards Brenmiller Energy Ltd, highlighting its position in the renewable energy sector as a favorable investment choice in the current market landscape.
Trade with 70% Backtested Accuracy
Analyst Views on BNRG
About BNRG
About the author
Brenmiller Energy (BNRG) to Implement 7-for-1 Reverse Split on January 23, 2026
- Reverse Split Announcement: Brenmiller Energy has announced a 7-for-1 reverse split effective after market close on January 23, 2026, reducing its outstanding shares from approximately 5.01 million to about 716,000, which aims to increase the share price and attract more investor interest.
- Shareholder Approval: The reverse split plan was approved by shareholders on January 13, reflecting confidence in the company's future and providing support for its continued listing on the Nasdaq Capital Market.
- Trading Schedule: The company's shares are expected to begin trading on a post-split basis on January 26, 2026, under the same ticker symbol BNRG, ensuring convenience for investors during the transition.
- Authorized Capital Unchanged: Despite the significant reduction in outstanding shares, the company's authorized share capital will remain unchanged, indicating that Brenmiller retains the capacity for future financing or equity adjustments to support its business growth.
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
Brenmiller Energy Unveils Technology Roadmap 2030: Delivering 50% Performance Gains at Half the Cost for Thermal Energy Storage
Next-Generation Technology: Brenmiller Energy is set to launch its bGen ONE™ thermal battery in 2026, featuring a 50% performance increase and improved efficiency through innovative heating concepts, while also planning continuous advancements every 12-18 months until 2030.
Commercial Growth: The company has established itself as a leader in thermal energy storage with over $500 million in commercial opportunities and 103 MWh of deployed projects, focusing on zero-emission solutions that enhance project margins and support renewable energy integration.
DarioHealth Announces CFO Transition
Leadership Change at DarioHealth: Zvi Ben-David, the Chief Financial Officer of DarioHealth Corp., will retire on May 15, 2025, and will be succeeded by Chen Franco-Yehuda, who brings extensive financial leadership experience in the healthcare sector.
Company Growth and Transition: Under Ben-David's tenure, DarioHealth transformed into a comprehensive digital health platform, and the company aims to leverage Franco-Yehuda's expertise for continued innovation and growth in managing chronic conditions.
Brenmiller Energy's bGen™ ZERO Wins Gold at 2025 Edison Awards
Brenmiller Energy Award: Brenmiller Energy Ltd. received a gold Edison Award for its bGen™ ZERO thermal energy storage system in the Energy Storage and Management category, recognizing its innovation and impact on renewable heat solutions.
Recognition and Impact: The bGen™ technology has also been acknowledged as one of TIME Magazine's Best Inventions of 2023 and has received several other accolades, highlighting its role in transforming energy consumption and supporting utility-scale renewables.
Brenmiller Energy (BNRG) to Implement 7-for-1 Reverse Split on January 23, 2026
- Reverse Split Announcement: Brenmiller Energy has announced a 7-for-1 reverse split effective after market close on January 23, 2026, reducing its outstanding shares from approximately 5.01 million to about 716,000, which aims to increase the share price and attract more investor interest.
- Shareholder Approval: The reverse split plan was approved by shareholders on January 13, reflecting confidence in the company's future and providing support for its continued listing on the Nasdaq Capital Market.
- Trading Schedule: The company's shares are expected to begin trading on a post-split basis on January 26, 2026, under the same ticker symbol BNRG, ensuring convenience for investors during the transition.
- Authorized Capital Unchanged: Despite the significant reduction in outstanding shares, the company's authorized share capital will remain unchanged, indicating that Brenmiller retains the capacity for future financing or equity adjustments to support its business growth.
Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%
- Take-Private Agreement Signed: Fonar Corp announced the signing of a definitive agreement for a take-private sale, resulting in a 24.5% surge in pre-market shares to $18.25, indicating strong market confidence that could provide financial backing for future growth.
- Strong Market Reaction: The stock's robust performance in pre-market trading reflects optimistic investor sentiment regarding the privatization deal, potentially attracting more investor interest and enhancing the company's overall market capitalization.
- Significant Industry Impact: Fonar's privatization move may trigger similar actions among other medical device companies, prompting more firms in the sector to consider privatization to enhance operational efficiency and shareholder value.
- Future Strategic Direction: By going private, Fonar is expected to concentrate resources on its core business and optimize its operational model, thereby strengthening its market position and profitability in a highly competitive healthcare market.
Brenmiller Energy Unveils Technology Roadmap 2030: Delivering 50% Performance Gains at Half the Cost for Thermal Energy Storage
Next-Generation Technology: Brenmiller Energy is set to launch its bGen ONE™ thermal battery in 2026, featuring a 50% performance increase and improved efficiency through innovative heating concepts, while also planning continuous advancements every 12-18 months until 2030.
Commercial Growth: The company has established itself as a leader in thermal energy storage with over $500 million in commercial opportunities and 103 MWh of deployed projects, focusing on zero-emission solutions that enhance project margins and support renewable energy integration.
DarioHealth Announces CFO Transition
Leadership Change at DarioHealth: Zvi Ben-David, the Chief Financial Officer of DarioHealth Corp., will retire on May 15, 2025, and will be succeeded by Chen Franco-Yehuda, who brings extensive financial leadership experience in the healthcare sector.
Company Growth and Transition: Under Ben-David's tenure, DarioHealth transformed into a comprehensive digital health platform, and the company aims to leverage Franco-Yehuda's expertise for continued innovation and growth in managing chronic conditions.
Brenmiller Energy's bGen™ ZERO Wins Gold at 2025 Edison Awards
Brenmiller Energy Award: Brenmiller Energy Ltd. received a gold Edison Award for its bGen™ ZERO thermal energy storage system in the Energy Storage and Management category, recognizing its innovation and impact on renewable heat solutions.
Recognition and Impact: The bGen™ technology has also been acknowledged as one of TIME Magazine's Best Inventions of 2023 and has received several other accolades, highlighting its role in transforming energy consumption and supporting utility-scale renewables.
